The results of the previously conducted clinical study on the safety of combined astaxanthin/crocetin tablets were recently been published in an academic journal, as reproduced below.

[Study Objectives]
The safety of combined astaxanthin/crocetin tablets was evaluated in human subjects for one month.

[Method of experiments]
Thirty-six healthy adults of both sexes took combined astaxanthin/crocetin tablets (each tablet containing 0.6 mg astaxanthin and 0.75 mg crocetin) via the oral route for 4 weeks. Volunteers were divided into three groups according to dose: 5 tablets/day; 10 tablets/day; and 30 tablets/day. Each subject visited the hospital at four times (at the start of the study, 2 and 4 weeks after the start of the study, and 2 weeks after the end of the study) to undergo examination and checks. These involved physical examination (blood-pressure measurement) laboratory tests (hematology) and a questionnaire survey of subjective symptoms.

[Results]
No parameter showed a marked change and no adverse event was seen after intake of the test product. The results endorse the safety of taking combined astaxanthin/crocetin tablets for periods up to 4 weeks at a dose level of up to 30 tablets per day.
Specifications of the article

Journal: *Journal of Nutritional Food* Vol. 12 No. 1, 1–12

Title: Safety study of overdose of tablets containing astaxanthin and crocetin in healthy adults

Authors: Yukari Arakawa¹, Masaki Fujishima¹, Toru Mizoguchi¹, Isao Takehara², Ikuo Fukuhara³

Affiliation: 1) Sun Chlorella Corporation, 2) New Drug Development Research Center, Incorporated, 3) Fukuhara Hospital

This leaflet reproduces presentations made in scientific journals or meetings and is not intended for sales or promotion of any product.